Hospira and healthcare IT firm Cerner are joining forces to develop the companies' infusion pump information platform, building on previous efforts to better integrate Hospira's infusion pumps with Cerner's electronic medical record systems.
Market-access contractor DKSH has signed a deal with Actelion Pharmaceuticals to help the company bolster its position in Asia.
While San Diego-based Pfenex's primary focus isn't on vaccines, the company gained a big backer in the space Monday with the announcement that the U.S. government has agreed to work with the biotech on its anthrax vaccine candidate for bioterror protection.
Singapore-listed Asian American Medical Group said it paid S$19.6 million ($13.9 million) to buy 60% of Rich Tree Land to develop an oncology diagnostics and treatment center in Zhuhai, southern China.
Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.
An exit by Janssen Pharmaceuticals from a seven year alliance with Hutchison MediPharma (HMP) to develop a novel inflammation/immunology candidate, HMPL-507, will see the HK-based firm carry-on independently, according to a press release.
Guardant Health has been charging full speed ahead with its liquid biopsy technology, inking deals and scoring new funds to expand the reach for its test. In its latest foray the company is teaming up with Flatiron Health to build a cloud-based platform that draws on its genomics data to accelerate cancer drug development.
Genetic data has already proven its clinical benefits, but still has a ways to go when it comes to consumerization, as evidenced by the demise of 23andMe's saliva-based Personal Genome Test at the hands of the FDA.
The word that China's top CRO WuXi PharmaTech would delist from the U.S. in a management-led $3.3 billion buyout opens up more paths to deal-making that may not reach the public as quickly.
China-focused Decheng Capital said a deal by Roche valued at $425 million for U.S.-based antibiotic diagnostic firm GeneWeave is an important milestone for the firm and the prospects of bringing a sorely needed product into the China market.